Ferroptosis inhibitors: mechanisms of action and therapeutic potential
Cellular and Molecular Life Sciences · 2025-12-19 · 82 (1)
DOI: 10.1007/s00018-025-05958-5 ↗At a glance
Übersichtsarbeit in Cellular and Molecular Life Sciences, published online on 2025-12-19. Written by Kun Duo and 8 co-authors. Institution: College of Pharmacy, Ningxia Medical University, Ningxia Hui Autonomous Region, Yinchuan, 750004, China. Major MEDLINE topics: Ferroptosis. Cited 54 times so far (Crossref); 135 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Key Research and Development Program of China, Key Research and Development Program of Ningxia, National Natural Science Foundation of China.
Abstract (original language)
Ferroptosis is a regulated form of cell death characterized by iron-dependent lipid peroxidation. It plays a crucial role in various pathological conditions, including neurodegenerative diseases, cancer, ischemia-reperfusion injury, and organ failure. This review systematically explores the key mechanisms underlying ferroptosis, including polyunsaturated fatty acid-containing phospholipid (PUFA-PL) peroxidation, iron metabolism, and mitochondrial dysfunction. Additionally, we summarize major endogenous ferroptosis defense systems, including the SLC7A11-glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis, the ferroptosis suppressor protein 1 (FSP1)-ubiquinol (CoQH₂) system, the mitochondrial dihydroorotate dehydrogenase (DHODH)-CoQH₂ pathway, and the guanosine triphosphate cyclohydrolase 1 (GCH1)-tetrahydrobiopterin (BH4) pathway, which act as critical brakes on ferroptosis. Furthermore, we discuss various small-molecule inhibitors targeting ferroptosis, categorized by their mechanisms of action, including iron chelators, lipid peroxidation inhibitors, antioxidants, and regulatory pathway modulators. Recent advances in pharmacological strategies and their potential therapeutic applications are also highlighted.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Ningxia Medical University, Ningxia Hui Autonomous Region, Yinchuan, 750004, China.
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China. hy050344@163.com.
- College of Pharmacy, Ningxia Medical University, Ningxia Hui Autonomous Region, Yinchuan, 750004, China. drcaizhenyu@tongji.edu.cn.
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China. drcaizhenyu@tongji.edu.cn.
Funding
- National Key Research and Development Program of China
- Key Research and Development Program of Ningxia
- National Natural Science Foundation of China
- Shanghai Committee of Science and Technology
- Fundamental Research Funds for the Central Universities
Cite
APA
Duo, K., Feng, X., Tian, X., Wang, F., Zhao, Y., Yu, J., Liu, Y., He, Y., & Cai, Z. (2025). Ferroptosis inhibitors: mechanisms of action and therapeutic potential. Cellular and Molecular Life Sciences, 82(1). https://doi.org/10.1007/s00018-025-05958-5
Vancouver
Duo K, Feng X, Tian X, Wang F, Zhao Y, Yu J, et al. Ferroptosis inhibitors: mechanisms of action and therapeutic potential. Cellular and Molecular Life Sciences. 2025;82(1). doi:10.1007/s00018-025-05958-5
BibTeX
@article{Duo2025,
author = {Duo, Kun and Feng, Xiaona and Tian, Xiaofang and Wang, Fang and Zhao, Yaxing and Yu, Jianqiang and Liu, Yue and He, Yuan and Cai, Zhenyu},
title = {Ferroptosis inhibitors: mechanisms of action and therapeutic potential},
journal = {Cellular and Molecular Life Sciences},
year = {2025},
volume = {82},
number = {1},
doi = {10.1007/s00018-025-05958-5}
}
EUVIMED